(Q80051658)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17390117%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

[Endogenous anticoagulant therapy for sepsis. Success and failure] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17390117%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

1 reference

C J Wiedermann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17390117%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17390117%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17390117%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17390117%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17390117%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

537-42, 544

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17390117%20AND%20SRC:MED&resulttype=core&format=json

Improvement in coagulation markers with antithrombin--beneficial in severe sepsis?

28 December 2019

cites work

1 reference

12 December 2020

Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

1 reference

12 December 2020

Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly

1 reference

12 December 2020

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

1 reference

12 December 2020

The efficacy of drotrecogin alfa depends on severity of illness

1 reference

12 December 2020

Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis

1 reference

12 December 2020

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

1 reference

12 December 2020

Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis

1 reference

12 December 2020

Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

1 reference

12 December 2020

A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis

1 reference

12 December 2020

Risks and benefits of activated protein C treatment for severe sepsis

1 reference

12 December 2020

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis

1 reference

12 December 2020

A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis

1 reference

12 December 2020

Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question

1 reference

12 December 2020

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

1 reference

12 December 2020

Baseline severity of sepsis in subjects of the prowess and the Kybersept clinical trials on endogenous anticoagulants

1 reference

12 December 2020

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

1 reference

12 December 2020

Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin

1 reference

12 December 2020

Treatment of purpura fulminans in meningococcemia with protein C concentrate

1 reference

12 December 2020

Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial

1 reference

12 December 2020

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

12 December 2020

Bioethics, the Surviving Sepsis Campaign, and the industry

1 reference

12 December 2020

Activated protein C: do more survive?

1 reference

12 December 2020

When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated)

1 reference

12 December 2020

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

1 reference

12 December 2020

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety

1 reference

12 December 2020

Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials

1 reference

12 December 2020

Substantiating the concerns about recombinant human activated protein C use in sepsis

1 reference

12 December 2020

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

12 December 2020

10.1007/S00108-007-1840-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17390117%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference